Probing the Subcellular Distribution of Phosphatidylinositol Reveals a Surprising Lack at the Plasma Membrane

James P. Zewe, April Miller, Sahana Sangappa, Rachel C. Wills, Brady D. Goulden* and Gerald R. V. Hammond

Department of Cell Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
*current address: Department of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Running Title: Subcellular distribution of PI

Keywords: PtdIns; Lipids; Phospholipids;

34,312 characters.

Summary. Zewe et al develop approaches to map the subcellular distribution of the major phospholipid, phosphatidylinositol (PI), revealing that the lipid is present in most membranes except for plasma membrane, where it is mainly found as PI4P and PI(4,5)P_2.

1 **Abstract**

The polyphosphoinositides (PPIn) are central regulatory lipids that direct membrane function in

eukaryotic cells. Understanding how their synthesis is regulated is crucial to revealing these

lipids' role in health and disease. PPIn are derived from the major structural lipid,

phosphatidylinositol (PI). However, although the distribution of most PPIn have been

characterized, the subcellular localization of PI available for PPIn synthesis is not known. Here,

we have used several orthogonal approaches to map the subcellular distribution of PI, including

localizing exogenous fluorescent PI, as well as detecting lipid conversion products of

endogenous PI after acute chemogenetic activation of PI-specific phospholipase and 4-kinase.

We report that PI is broadly distributed throughout intracellular membrane compartments.

However, there is a surprising lack of PI in the plasma membrane compared to the PPIn. These

experiments implicate regulation of PI supply to the plasma membrane, as opposed to

regulation of PPIn-kinases, as crucial to the control of PPIn synthesis and function at the PM.

1 Introduction

The polyphosphoinositides (PPIn) are crucial regulatory lipids in eukaryotic physiology. They

direct protein localization and/or activation on the cytosolic face of membranes, thereby

controlling myriad cellular processes such as membrane traffic, lipid exchange, ion transport,

cell signaling and cytoskeletal dynamics (Balla, 2013; Dickson and Hille, 2019). Structurally,

PPIn consist of phosphorylated derivatives of the major glycerophospholipid,

phosphatidylinositol (PI). The enzymology of PPIn synthesis and turnover is well understood,

and an important endeavor in cell biology seeks to understand the control of cellular physiology

in both health and disease by understanding regulation of PPIn enzymes.

When considering their relative abundance, the PPIn have an outsized role in membrane

function; they account for only ~2-10% of inositol lipid, with the remainder being PI (Anderson et

al., 2013; Traynor-Kaplan et al., 2017). PI itself accounts for around 10% of total phospholipid

(Vance, 2015), so it follows that PPIn constitute less than 1% of total phospholipid. On the other

hand, PI is an important structural component of membranes, and its synthesis probably

accounts for positive effects of dietary inositol supplementation, as opposed to effects on

quantitatively minor PPIn (Michell, 2018).

PI is synthesized on the cytosolic face of the ER (Bochud and Conzelmann, 2015), from where

some is "flopped" to the luminal leaflet for the synthesis of glycosylphosphatidylinositol-linked

proteins (Vishwakarma et al., 2005). The remaining PI has been shown to be distributed fairly

evenly across most organelle membranes by sub-cellular fractionation (Vance, 2015). However,

in such studies, the fraction of PI in the cytosolic face of the membrane (and thus available for

PPIn synthesis) is not known. Furthermore, the process of sub-cellular fractionation exposes

membranes to phosphatases than can remove labile PPIn phosphate monoesters,

consequently overestimating PI and underestimating PPIn. Therefore, it is currently unclear how

much PI is available for PPIn synthesis in cytosolic membrane leaflets – and hence, whether the

crucial regulatory step is the control of PI kinases activity, or supply of PI substrate.

A prominent example of this problem is at the plasma membrane (PM), which contains the

majority of PI(4,5)P_2 and largest share of PI4P (Hammond and Balla, 2015). Although these

lipids are ≤ 1% of total cellular phospholipid, they are specifically enriched at the PM, whereas

the much more abundant PI is not; so PPIn likely account for a larger share of the PM inositol

lipid. How big a share? Estimates of the fraction of cellular phospholipids at the PM vary by two

orders of magnitude, from 0.5% (Schmick et al., 2014) to 50% (Lange et al., 1989); assuming an

intermediate fraction of 14% (Griffiths et al., 1989), $PI(4,5)P_2$ and PI4P may therefore be around

~7% of PM phospholipid, not far from the roughly 10% PI assumed if it were uniformly

distributed among organelles including the PM. This fits with measurements of red blood cells,

which only contain PM, where PI, PI4P and $PI(4,5)P_2$ are present in approximately equal

quantities (Ferrell and Huestis, 1984). It also fits with observations from isolated cardiomyocyte

PM, which has a limited supply of PI for PPIn re-synthesis after stimulation of phospholipase C

(Nasuhoglu et al., 2002). In general though, there is scant evidence as to the relative

abundance of PI in various organelles that is actually available for PPIn synthesis.

In this study, we have applied a series of distinct approaches to map the subcellular distribution

of PI in intact, living cells. These included loading cells with fluorescent PI derivatives, and

probing cells for diacylglycerol (DAG) and PI4P after inducing acute conversion of endogenous

PI to these lipids. Whilst each approach carries significant caveats, collectively our results

illustrate a wide subcellular distribution of PI, but a surprising lack at the PM.

1 Results

Intracellular distribution of exogenous fluorescent PI.

Lipids with fluorescent fatty acids have long been used as tracers for the traffic, metabolism and

steady-state distribution of native lipids (Lipsky and Pagano, 1985; Struck and Pagano, 1980).

In these experiments, exogenous lipids are applied to cells as either liposomes or via serum

albumin carriers, from where they spontaneously incorporate into the exoplasmic leaflet of the

PM. From here, the lipids follow the same cellular fate as the native molecules: they are either

endocytosed, or else be flipped by native translocases. The flipped lipids may then traffic from

the cytosolic leaflet of the PM to other organelles via vesicular and non-vesicular pathways,

being metabolized along the way (Pagano et al., 1983). We attempted this approach with

inositol lipids, using commercially available TopFluor®-fatty acid conjugated lipids. We reasoned

this was a potentially viable approach, since native PI translocase and/or scramblase activities

have been reported in mammalian cells, albeit with weaker activity compared to

aminophospholipid translocases (Bütikofer et al., 1990; Wang et al., 2018).

We loaded COS-7 green monkey fibroblasts with TopFluor lipids using bovine serum albumin

(BSA) for fifteen minutes before back-extracting the outer PM leaflet with excess BSA (figure

1A). As a positive control, we loaded cells with TopFluor-PS. This lipid rapidly incorporated into

the PM and intracellular vesicles (figure 1A, top panel). It could not be back-extracted, since the

PS is rapidly flipped to the inner leaflet by endogenous aminophospholipid translocases (figure

1A), exactly as described previously (Kay et al., 2012). On the other hand, TopFluor-PI(4,5)P$_2$

intensely labelled the plasma membrane, but was almost entirely back-extracted, leaving only

punctate signal that presumably corresponded to endocytosed lipid in the exoplasmic leaflet

(figure 1A, middle panel). The majority of TopFluor-PI was also back-extracted from the PM.

However, in addition to the internalized vesicles, a substantial intracellular labelling appeared

during loading that remained after back-extraction (figure 1A, bottom panel). This suggested

that PI was indeed flipped into the inner PM leaflet, but in contrast to PS, was subsequently

transported rapidly to other organelles.

Figure 1: Fluorescent PI is not enriched at the PM. (**A**) **Internalization of fluorescent lipids**. COS-7 cells were loaded at 37˚C with the indicated acyl-conjugated TopFluor lipids complexed with BSA. After 15 min, a 20-fold excess of un-complexed BSA was used to back-extract lipid remaining in the outer PM leaflet. (**B**) **Loaded TopFluor-PI is not metabolized**. COS-7 cells were loaded or loaded and back-extracted as in A. Lipids were then extracted and resolved by thin-later chromatography. (**C-E**) **Loaded TopFluor-PI labels the Golgi** (C)**, ER** (D) **and mitochondria** (E). COS-7 cells that had been transfected with mCherry-β4-GalT^{N82} (C), iRFP-Sec61β (D) or COX8A^{N19}x2-mCherry (E) were loaded and back-extracted as in (A). Scale bar = 20 μm in all panels; insets are 10.9 μm (C) or 7.3 μm (D-E). Data are representative of three or more experiments.

Previous work has shown a similar, though much more rapid, translocation of NBD-labelled PI

from the cell surface to intracellular membranes in 3T3 pre-adipocytes, though not in Chinese

hamster ovary cells (Ting and Pagano, 1990). That rapid translocation was due to an

exoplasmic phospholipase C activity in 3T3 cells that cleaved PI into the rapidly flip-flopping

lipid, DAG. Therefore, we extracted lipids from our COS-7 cells loaded with TopFluor-PI after

back extraction for analysis by thin-layer chromatography: we observed no such metabolism of

PI, which migrated identically to the TopFluor-PI standard and was well resolved from TopFluor-

DAG (figure 1B). Thus, COS-7 cells appeared to traffic exogenous fluorescent PI molecules

from the PM and distribute it to intracellular membranes intact.

To identify these intracellular membranes, we performed high-resolution confocal microscopy of

live cells expressing fluorescent protein conjugated markers of the most abundant intracellular

membranes. With this approach, we could detect clear enrichment of the lipid at Golgi

membranes (figure 1C), the endoplasmic reticulum (ER; figure 1D) and mitochondria (figure

1E). Surprisingly, relatively little TopFluor-PI was observed at the PM, in stark contrast to the

observations with TopFluor-PS (figure 1A). To the extent that TopFluor-PI traffic and steady-

state distribution mirrors natural PI, this implies that PI is widely distributed in the cell, though

notably absent from the PM, one of the most active compartments of phosphoinositide

metabolism and function. However, these experiments still bear the significant caveat that the

exogenous, derivatized PI may not reflect the endogenous distribution and traffic of native PI.

They also do not furnish information on the transbilayer distribution of these lipids within the

labelled organelles. For these reasons, we next turned our attention to approaches that could

probe for the presence of endogenous PI in the cytoplasmic face of organelle membranes.

An acutely activatable PI-PLC to probe organelle PI content

In lieu of a bona fide PI biosensor for use in living cells, the PI-specific PLC from *Listeria*

monocytogenes can be used as an indirect probe: the PI-PLC converts PI to inositol phosphate

and DAG, the latter of which can then be detected with the selective, high affinity C1ab domain

from PKD1 (Kim et al., 2011). The PI-PLC retains high activity despite its largely cytosolic

localization, revealing highly dynamic DAG-containing structures that are not easily attributable

to specific organelles of origin. However, prolonged exposure of cells to a degradative enzyme

like a phospholipase risks extensive damage to membranes and activation of containment and

repair processes. In other words, the DAG distribution may not closely reflect the intracellular

origin of the PI, which may have been generated several hours before imaging in these

transfection experiments (Kim et al., 2011).

To circumvent this problem, we attempted to make an acutely activatable PI-PLC. Recruitment

of lipid-modifying enzymes to membranes is one commonly used approach to accomplish this

(DeRose et al., 2013), but the high basal activity of cytoplasmic PI-PLC (Kim et al., 2011)

precluded this approach. We attempted to make mutants of *Bacillus cereus* PI-PLC with

reduced (but not abolished) catalytic activity based on previously reported activity of the

recombinant enzyme (Gässler et al., 1997). However, none of the mutants we screened

retained sufficient activity to yield DAG production upon recruitment, whilst also showing low

basal activity before recruitment. We also attempted to incorporate caged lysine into the *L.*

monocytogenes enzyme using unnatural amino acids (Courtney and Deiters, 2018), though

were unable to obtain expression of the mutated enzyme.

Finally, on inspecting the crystal structure of the *L. monocytogenes* enzyme, we noted that the

protein consists of two well-defined amino and carboxy-terminal lobes with a single linking loop,

and also possessed amino and carboxy termini that were close to one another (Moser et al.,

1997). We therefore reasoned that the enzyme could be expressed as separate lobes that could

be induced to form a functional enzyme after chemically-induced dimerization of FKBP (FK506-

binding protein) and FRB (FKBP12 and Rapamycin binding domain of mTor) fused to the amino

and carboxy terminal domains, respectively (figure 2A).

Figure 2: Chemically-induced dimerization of a split PI-PLC induces intracellular accumulation of DAG. (**A**) **Experimental set-up:** Rapamycin-induced dimerization of FKBP-fused N-terminal 187 residues of PI-PLC (cyan) with the FRB-fused C-terminal 100 residues (orange) reconstitutes the active enzyme, though no visible change in the cytosolic localization of the TagBFP2/iRFP-fused enzyme fragments is observed (confocal images at right). (**B**) **DAG accumulation on cytosolic leaflets of intracellular organelles**, with the greatest increases in the Golgi and endo/lysosomal compartments. Zero or comparatively minor changes were observed in mitochondria, peroxisomes or the ER. Cells were expressing GFP-PKD1-C1ab to detect DAG, the indicated organelle markers fused to mCherry or mKO (magenta), FKBP-PI-PLC^{N187} and FRB-PI-PLC^{C100} (not shown); they were treated with 1 μM rapamycin at time 0. Inset regions are 15 μm and serve as scale bars. (**C**) **Anchoring PI-PLC^{N187} to the mitochondrial outer membrane shows transient accumulation of DAG after recruitment of PI-PLC^{N100}**. Cells were transfected as in B, but with AKAP^{N31}—fused PI-PLC^{N187} replacing the unanchored version in B. Inset = 30 μm and serves as scale bar In both B and C, the curves at right show the mean change in C1ab reporter intensity at each compartment, with s.e.m. shaded. The violin plots show area under the curve, with the number of cells (pooled across 3-6 independent experiments), the sum of signed ranks (W) and P-value from a two-tailed Wilcoxon signed rank test comparing to a null hypothesis area under the curve value of 0.

Expression of TagBFP2-FKBP-PLC^{N187} and PLC^{C100}-FRB-iRFP showed both enzymes

distributed in the cytoplasm, as observed with the full-length enzyme (Kim et al., 2011); no

change in localization was observed when dimerization was induced with rapamycin (see

micrographs in figure 2A). However, a GFP-C1ab DAG biosensor expressed in the same cells

began to show an intense juxtanuclear accumulation and many small, punctate structures in the

cytoplasm (figure 2B). We identified many of these structures through co-localization with co-

expressed organelle markers (figure 2B). The juxtanuclear accumulation occurred in and around

the Golgi membranes marked by ManII^{N102}. Many of the cytoplasmic puncta showed co-

localization with Rab5 or LAMP1 as markers of the early and endo/lysosomal compartments,

respectively. Surprisingly, and in contrast to results with TopFluor-PI, we did not see substantial

accumulation in the ER or mitochondria, nor peroxisomes. A small, statistically significant

change in localization of C1ab fluorescence with peroxisomes and the ER was observed,

though these may simply be due to chance overlap given the large increases in the number of

cytoplasmic C1ab-labelled puncta. None seemed to precisely correspond to these organelles as

they did for the Golgi and endosomes.

The most parsimonious explanation for our failure to observe PLC-mediated DAG generation at

ER and mitochondria would be that little PI remains in the cytosolic leaflets of these organelle

membranes. However, it is also possible that the cytosolic enzyme is not active on these

membranes, or that the C1ab probe does not efficiently recognize DAG in these membrane

contexts. Moreover, substantial recruitment of C1ab to DAG-replete membranes like the Golgi

may also deplete the probe available to detect smaller pools elsewhere. To more directly probe

for the presence of PI substrate, we targeted the amino-terminal lobe of PI-PLC to the outer

mitochondrial membrane by fusing it to the amino-terminal 31 amino acids of AKAP1 (Ma and

Taylor, 2002), with the aim of recruiting the carboxyl-terminal half to reconstitute the enzyme at

the organelle surface (figure 2C). Indeed, we could see robust recruitment of PLC^{C100}-FRB-iRFP

with a time constant of approximately 3 minutes, which now yielded a substantial increase in

C1ab labelling of the mitochondria with similar kinetics (figure S2B, D). Interestingly, although

DAG appeared initially throughout the mitochondrial surface, the labelling rapidly resolved into

small puncta. We do not know the nature of this re-localization of DAG, which could conceivably

be phase separation or traffic of the accumulated lipid. It may, however, explain the failure to

observe substantial labelling of the mitochondria by the cytosolic enzyme in our experiments

(figure 2B) or previous studies (Kim et al., 2011).

Figure 3: Very little PI can be converted to DAG at the PM. (**A**) **PM-specific dimerization of split PI-PLC**
induces very little DAG compared to PI(4,5)P$_2$-specific PLC. Cells were transfected with PI-PLC[C100]-FRB, PM-
targeted Lyn[N11]-FKBP-PI-PLC[N100] and GFP-PKD1-C1ab to detect DAG. Rapamycin was used to induce PI-PLC
reconstitution at the PM, or else endogenous PLCβ was activated by G$_q$-coupled agonists ATP (to activate
endogenous P2Y receptors) or carbachol (CCh, to activate over-expressed muscarinic M3 receptors). TIRFM images
are color-coded to represent fluorescence intensity relative to pre-stimulus levels (F_t/F_{pre}) as indicated. Inset region is
5 μm and serves as scale bar for images in A. The line graphs show mean F_t/F_{pre} with s.e.m. shaded; P values are
derived from Dunn's multiple comparison test comparing to time 0, following Friedman's test (Friedman statistic =
49.16, PI-PLC, P = 0.045; 497.0, ATP, P < 10^{-4}; 282.3, CCh; P < 10^{-4}). Where not indicated, the P value from Dunn's
> 0.05. The violin plots show area under the curve analysis of the line graphs with the number of cells from 3
independent experiments, with results of a Kruskal-Wallis test and P values from a post-hoc Dunn's multiple
comparison test indicated. (**B**) **Split PI-PLC induces translocation of Nir2 to ER-PM contact sites**. Cells were
transfected with PM-targeted split PI-PLC and stimulated with rapamycin or ATP as in (A). Translocation of GFP-Nir2
was recorded; images show representative TIRFM images with fluorescence normalized to pre-stimulus levels
(F_t/F_{pre}). Scale bar = 10 μm. The line graphs show mean F_t/F_{pre} with s.e.m. shaded; the violin plots show area under
the curve analysis of the line graphs with the number of cells from 3 independent experiments indicated, along with
results of Wilcoxon signed rank test comparing each population to a hypothesized AUC of 0, as well as a Mann-
Whitney U test comparing the differences between AUC after ATP or rapamycin stimulation.

We attempted similar experiments with the ER. However, fusion of PI-PLC[N187] to the amino-

terminal domain of STIM1 exhibited a mis-localized, punctate distribution in addition to the

normal ER morphology, whereas fusion of PLC[C100] to the SAC1 carboxy-terminal TM domains

failed to recruit cytosolic PI-PLC[N187] (J.P.Z., R.C.W. and G.R.V.H., unpublished observations).

Therefore, we were unable to definitively probe the cytosolic face of the ER with this approach.

We also produced a PM-targeted PI-PLC[N187] by fusion to the myristoylated and palmitoylated

amino-terminal domain of Lyn kinase (figure 3A). Dimerization with rapamycin induced

translocation of PI-PLC[C100] to the PM that was largely complete in 1 min (figure S2 B, C) and the

formation of a few C1ab-labelled puncta in these cells, visible by total internal reflection

microscopy (TIRFM). Nonetheless, the overall increase in DAG was small and transient. In

contrast, activation of $PI(4,5)P_2$-specific PLCβ by activation of either endogenous purinergic, or

over-expressed muscarinic M3 receptors caused a much larger increase in DAG (figure 3A).

This result would be consistent with the notion that in the PM, levels of PI are much lower

compared to $PI(4,5)P_2$; hydrolysis of a relatively small fraction of $PI(4,5)P_2$ induced by ATP still

produces a much greater increase in DAG than PI-PLC-mediated hydrolysis of PM PI.

An alternative explanation to these data could be that the Lyn amino-terminal fusion does not

orient the split-PI-PLC in an orientation conducive to activity in the PM; the few DAG puncta that

we observe may instead be produced on organelle membranes that happen to approach close

enough to the PM for the re-combined PI-PLC to hydrolyze their PI. Therefore, in order to test

whether PM-targeted PI-PLC indeed generated DAG at the PM, we sought an alternative route

to detect PM-localized DAG. To this end, we took advantage of the fact that translocation of the

ER-localized PI/phosphatidic acid transfer protein Nir2 requires PM DAG to translocate to ER-

PM contact sites (Kim et al., 2015). As shown in figure 3B, dimerization of split PI-PLC at the

PM induced translocation of Nir2 to puncta as seen in TIRFM; this occurred to virtually the same

extent as with activation of endogenous PLCβ with ATP. Although there were small differences

in the kinetics of the translocation, no significant difference between the two stimuli was

detected (figure 3B). Together with our observations with the C1ab DAG sensor, these data

imply that sufficient PI is present at the PM that, when converted to DAG, can recruit Nir2; but it

is far less than the quantity produced when hydrolysis of $PI(4,5)P_2$ is activated by endogenous

PLCβ.

Figure 4: PI-PLC leads to little or no depletion of PPIn on Golgi and endosomes (**A**) **or PM** (**B**). Cells were transfected with PI-PLC[C100]-FRB, FKBP-PI-PLC[N100] (or PM-targeted Lyn[N11]-FKBP-PI-PLC[N100]) and GFP-PKD1-C1ab to detect DAG, along with the indicated PPIn biosensor. Dimerization and activation of PI-PLC was induced with 1 μM rapamycin as indicated. Images are confocal sections (A) or TIRFM (B). Scale bars = 20 μm. Inset = 10 μm for P4M and 15 μm for FYVE. Line graphs show the change in compartment specific fluorescence of C1ab (green) or the PPIn biosensor (magenta) normalized to pre-rapamycin levels (F_{pre}). The violin plots show area under the curve, with the number of cells (pooled across 3 independent experiments), the sum of signed ranks (W) and P-value from a two-tailed Wilcoxon signed rank test comparing to a null hypothesis area under the curve value of 0 (with a baseline of 1).

We also tested whether acute activation of PI-PLC reduced PI levels sufficiently to reduce levels

of phosphoinositides, as was previously reported for constitutive over-expression of the intact

enzyme (Kim et al., 2011). Notably, the large increase in C1ab after PI-PLC activation

correlated with a partial depletion of Golgi-associated PI4P biosensor, P4M (figure 4A).

However, within 15 min we could not detect decreases in endosomal association of PI3P

biosensor FYVE-EEA1 (figure 4A) nor PM PI(4,5)P$_2$ biosensor Tubby$_c$ (figure 4B). This could be

interpreted as a simple failure to sufficiently deplete the endosome or PM-associated PI levels.

Alternatively, it would be consistent with the PI pools utilized in synthesis of these lipids being

derived from other, non-PLC accessible sources that are not necessarily associated with these

organelles. Unexpectedly, we observed a small (~10%) but significant increase in PM PI4P

biosensor, P4M (figure 4B). It is possible that this results from a paradoxical increased supply of

PI to the PM, caused by the PI-PLC-induced translocation of Nir2 that we reported in figure 3B.

This would require the endogenous PI4K to consume Nir2-delivered PI before the PM-targeted

split PI-PLC, which would also be consistent with the failure of PI-PLC to deplete PI4P or

$PI(4,5)P_2$ in these experiments.

Overall, these data demonstrate that PI is widely distributed in intracellular cytosolic

membranes, though notably absent from the PM. These data are largely consistent with our

observations of fluorescent PI re-distribution, though there were a number of differences,

notably our failure to detect ER-associated PI. Therefore, we sought an alternative,

corroborative approach.

Acute conversion to PI4P as a probe for PI

We reasoned we could also detect the presence of PI via conversion to PI4P after recruitment

of a PI 4-OH kinase (PI4K), in a similar approach to detecting DAG derived from acutely re-

constituted PI-PLC. To this end, we selected PI4KIIIα (encoded by *PI4KA*, referred to as PI4KA

hereafter). The enzyme exists as a large, 700 kDa multi-subunit complex (Lees et al., 2017;

Dornan et al., 2018); however, the isolated carboxy-terminal fragment containing the helical and

catalytic domain (PI4KA[C1001]) retains activity and can complement Hepatitis C proliferation in

PI4KA knock-down cells (Harak et al., 2014). Therefore, we fused this fragment to FKBP to

facilitate chemically induced dimerization with FRB, targeted to distinct organelle membranes

(figure 5A). A catalytically inactive Asp[1957] to Ala mutant served as a negative control. PI4P was

detected with highly selective and unbiased probes for PI4P, namely the relatively low affinity

P4M domain (Hammond et al., 2014) and the higher affinity P4C domain (Weber et al., 2014;

Luo et al., 2015) from *Legionella* effectors SidM and SidC, respectively.

Figure 5: Compartment-specific recruitment of PI4KA reveals intracellular PI pools. (**A**) **Experimental set-up:**
Rapamycin-induced recruitment of FKBP-PI4KA^{N1001} by dimerization with compartment-specific FRB to induce PI4P
synthesis from endogenous PI, revealed with GFP-P4M or -P4C. (**B**) **PI4P accumulation on cytosolic leaflets of**
intracellular organelles, with the greatest increases in the Golgi and mitochondria, with barely detectable increases
in endosomes and ER. Peroxisomes show a large increase, but PI4P intensity also occurs outside of PMP-marked
compartments. Cells are expressing GFP-P4M or -P4C (green), compartment-specific FRB (magenta) and FKBP-
PI4KA^{N1001} (cyan) as indicated were treated with 1 μM rapamycin at time 0. Inset regions are 15 μm and serve as
scale bars. The line graphs at right show the mean change in PI4P reporter intensity at each compartment, with
s.e.m. shaded. The violin plots show area under the curve analysis of the curves, with the number of cells (pooled
across 2-4 independent experiments), Mann-Whitney U statistic and P-value from a two-tailed test. (**C**) **Peroxide-**
mediated inhibition of ER-associated SAC1 PI4P phosphatase reveals an endogenous pool of PI that can be

Kinetically, recruitment of FKBP-PI4KA^{C1001} occurred with a time constant of 1-2 min to each

organelle, with any PI4P biosensor recruitment occurring over a similar or slightly slower time

constant (figure S3). In terms of magnitude, recruitment of PI4KA^{C1001} to the Golgi induced a

rapid and dramatic increase in PI4P levels at the Golgi (figure 5B), consistent with our

observations with DAG after PI-PLC activation (figure 2B). Recruitment to Rab5- or LAMP1

positive endosomes and lysosomes produced a small but significant increase in PI4P, though

this was less marked than the increases in DAG after PI-PLC activation (figure 2B). On the

other hand, we could observe a dramatic increase in PI4P on the mitochondrial outer membrane

when recruiting PI4KA^{C1001}, and a marked increase at peroxisomal membranes (figure 5B).

Strangely, we noticed that in addition to producing PI4P in structures co-localizing with the

peroxisomal FRB-PMP, an increase was also observed at a compartment with morphology

consistent with mitochondria. We do not know if this is due to transfer of PI4P produced at

peroxisomes to the mitochondrial outer membrane, perhaps via contact sites (Valm et al.,

2017), or else direct synthesis of PI4P at mitochondrial membranes by a small pool of mis-

targeted PMP.

We could barely detect PI4P synthesis at the ER after PI4KA^{C1001} recruitment (figure 5B). We

reasoned that this was likely due to the presence of SAC1, a highly active PI4P phosphatase

present throughout the ER (Zewe et al., 2018). Inhibition of SAC1 with peroxide causes rapid

accumulation of PI4P at the ER, which has been interpreted as being due PI4P transfer from

other organelles (Zewe et al., 2018). We therefore reasoned that recruitment of PI4KA^{C1001}

during inhibition of SAC1 would cause a further increase in PI4P levels, due to conversion of

any PI already present in the ER. Indeed, this is exactly what we observed: there was a

substantial and highly significant increase in ER PI4P accumulation when active PI4KA^{C1001} was

recruited relative to the inactive control (figure 4C). Therefore, we could corroborate the

presence of PI in the ER suggested by the accumulation of TopFluor-PI there (figure 1D).

Figure 6: Recruitment of PI4K to the PM reveals a scarcity of PI. (**A**) **Recruitment of PI4KA^{N1001} shows no increase in PI4P or PI(4,5)P$_2$**. COS-7 cells imaged by TIRFM expressing GFP-P4Mx1 or Tubby$_c$-mCherry together with FKBP-PI4K^{N1001} and Lyn^{N11}-FRB were treated with 1 μM rapamycin at time 0 to induce dimerization. Scale bar = 20 μm. The curves at right show the mean change in reporter intensity, with s.e.m. shaded. The violin plots show area under the curve analysis of the curves, with the number of cells (pooled across 3 independent experiments) and the Mann-Whitney U statistic and P-value from a two-tailed test. (**B**) **PI4KB induces PI4P increases at the mitochondria but not the PM**. COS-7 cells were transfected with P4Mx1 to detect PI4P increases by confocal microscopy in conjunction with the indicated compartment-specific FRB and FKBP-PI4KB. Insets are 15 μm and serve as scale bars. Line graphs are means with s.e.m. shaded; inset violin plot shows area under the curve analysis, with number of cells (pooled across 3 independent experiments) and the Mann-Whitney U statistic and P-value from a two-tailed test. (**C**) **PI4KB is active in the PM**. COS-7 cells were co-transfected with PI(4,5)P$_2$ biosensor Tubby$_c$-GFP (green) and muscarinic M3 receptors, to stimulate PLCβ-induced PI(4,5)P$_2$ and PI4P depletion from the PM in response to carbachol treatment. Subsequent treatment with the muscarinic antagonist atropine induces re-synthesis of PI4P and PI(4,5)P$_2$ via endogenous PI4KA. Where indicated, the PI4KA inhibitor A1 was added at a 30 nM concentration. Images show confocal sections (bar = 20 μm) before stimulation, after addition of carbachol and after atropine addition as indicated. Curves are means with s.e.m. shaded. The violin plot shows area under the curve analysis for the post-atropine addition, with number of cells (three independent experiments), Kruskal-Wallis statistic and P value from a two-tailed test. P values between individual groups show are derived from a post-hoc Dunn's multiple comparison test.

In contrast, we could detect no increases in PI4P at the PM by TIRFM after recruiting PI4KA[C1001]

(figure 6A), despite efficient recruitment within 1 min (figure S3B, C), consistent with our

observations with PI-PLC (figure 3) and the distribution of TopFluor-PI (figure 1). We also saw

no increase in $PI(4,5)P_2$ detected with the low affinity Tubby c-terminal domain mutant,

$Tubby_c^{R332H}$ (Quinn et al., 2008), ruling out conversion of extra PI4P to this lipid (figure 6A). An

obvious interpretation of this result is that there is little PI resident in the PM available for

conversion to PI4P (or to $PI(4,5)P_2$). However, we wanted to rule out other interpretations –

specifically, that the PI4KA catalytic domain may be "biologically insufficient" to phosphorylate

PI in the PM without assistance from PI transfer proteins (Grabon et al., 2015). To this end, we

devised an experiment whereby the endogenous PM-associated PI4KA activity could be

replaced with an alternative activity. For this purpose, we selected PI4KIIIβ (PI4KB), the isoform

usually associated with PI4P synthesis at the Golgi (Balla and Balla, 2006). We made an FKBP

fusion of this enzyme: recruitment to mitochondria occurred within 1 min and caused

accumulation of PI4P in this membrane with a time course of approximately 11 min (figure 6B,

S4), demonstrating the fusion was active. On the other hand, as we observed for FKBP-

PI4KA[C1001], no increases in PI4P were observed after recruitment of FKBP- to the PM PI4KB

(which occurred within 1 min, figure S4) relative to an FKBP-only control (figure 6B).

We next sought to demonstrate that PI4KB can intrinsically be active at the PM, ruling out

biological insufficiency of PI4KB or that the enzyme has a preference for acyl chains found in

Golgi but not PM PI. One situation where a rapid increase in PM PI4P and $PI(4,5)P_2$ synthesis

occurs is after recovery from PLCβ-mediated depletion of these lipids following muscarinic M3

acetylcholine receptor activation (Willars et al., 1998). We overexpressed M3 receptors in COS-

7 cells expressing the Tubby c-terminal domain as a $PI(4,5)P_2$ reporter (figure 6C). Cells were

stimulated with carbachol for 2 min to activate PLCβ, then the muscarinic antagonist atropine

was added to shut off the PLC and facilitate $PI(4,5)P_2$ re-synthesis via PI4P (Nakanishi et al.,

1995). Control cells rapidly re-synthesized PM $PI(4,5)P_2$ within four minutes (figure 6C). We

then repeated this experiment whilst blocking the endogenous PI4KA activity with the highly

potent and selective inhibitor A1 (Bojjireddy et al., 2014); very little re-synthesis of $PI(4,5)P_2$

occurs under these conditions (figure 6C). Finally, we repeated the A1 treatment in cells in

which the A1-resistant FKBP-PI4KB was recruited to the PM: This led to a substantial recovery

of PM $PI(4,5)P_2$ synthesis, though this was slower than in controls and incomplete in the 15 min

period of the experimental recovery (figure 6C). Nonetheless, clear activity of PI4KB could be

demonstrated in the PM – arguing strongly that a failure to further increase PI4P (or PI(4,5)P$_2$)

levels in unstimulated cells is due to a scarcity of PI available for conversion.

Discussion

In this paper, we performed experiments to map the subcellular distribution of PI in intact, living

cells. We were particularly interested with respect to organelles that contain PPIn, since the

availability of PI substrate for PPIn synthesis has important implications for the regulation of

PPIn abundance and downstream physiology. We took three complimentary approaches: the

localization of an exogenous, fluorescent PI (figure 1); localization of DAG, converted from PI by

an acutely-activated PI-PLC (figures 2-4); and localization of PI4P, after acute conversion of PI

by a membrane-recruited PI4K (figures 5-6). Broadly speaking, these approaches demonstrated

the presence of PI in multiple intracellular membranes, but a relatively small amount (compared

to PPIn) at the PM (see the summary of results in table 1).

Each of the three approaches has significant caveats. Optical imaging of fluorescent lipids fails

to give information as to the bilayer distribution, so does not necessarily reflect the PI available

for conversion to PPIn by cytosolic PI kinases. Furthermore, the fluorescent moiety may disrupt

the traffic and distribution of the exogenous lipid; for example, whereas TopFluor-labelled PS

reflects closely the distribution of endogenous PS (Kay et al., 2012), NBD-labelled PS fails to

show enrichment at the cytosolic face of the PM (Martin and Pagano, 1987).

On the other hand, acute conversion of PI to DAG or PI4P by acute chemogenetic activation of

enzymes strictly reports endogenous, cytosolic leaflet-resident PI. Nevertheless, there are also

substantial confounds to these experiments. Breakdown of a large fraction of phospholipid in a

membrane to the much less polar DAG may dramatically alter bilayer properties (Alwarawrah et

al., 2016). Moreover, DAG can readily flop to the exoplasmic leaflet (Bai and Pagano, 1997), or

else be metabolized by DAG kinase, acyltransferases or lipases. Each process could

significantly limit translocation of the C1ab domain probe, perhaps explaining the transient DAG

accumulation observed at mitochondria before the signal resolves into a more punctate

distribution (figure 2C). Likewise, acutely-induced PI4P could be subject to phosphorylation or

dephosphorylation by PPIn enzymes, or else sequestration or transport by, for example, the

OSBP-related family of proteins (Olkkonen, 2015). Indeed, the presence of the PI4P

phosphatase Sac2 and the PI4P transfer protein OSBP at endosomes (Hsu et al., 2015;

Nakatsu et al., 2015; Dong et al., 2016) may explain our failure to induce significant PI4P

accumulation at endosomes (figure 5B and table 1). Certainly, conditions wherein the ER-

localized Sac1 phosphatase is limited allowed us to detect increased PI4P accumulation at the

ER compared to conditions where native Sac1 was still active (figure 5C).

Our most consistent finding from all three approaches was that they all failed to identify

substantial PM-associated pools of PI (table 1). Although surprising, this observation is

consistent with biochemical quantification from rapidly isolated PM sheets (Saheki et al., 2016).

This finding is significant, in that it moves the onus for regulating PM PPIn synthesis from the

PI4K-catalyzed PI phosphorylation to the supply of PI substrate for this enzyme.

The need for re-supply of ER-synthesized PI to the PM for PPIn synthesis has been known for a

good many years (Lapetina and Michell, 1973). Vesicular transport of PI4P or PI from the Golgi,

an organelle that we show is replete with both lipids, can contribute to PM $PI(4,5)P_2$ synthesis

(Szentpetery et al., 2010; Dickson et al., 2014). However, these contributions do not explain the

full capacity for PM synthesis, and the speed of the secretory pathway from the ER does not

match the rate at which PM pools of PPIn can be turned over; instead, the activity of PI transfer

proteins has been proposed to feed PPIn synthesis directly from the ER (Lapetina and Michell,

1973). More recently, specific PI transfer proteins such as Nir2 and TMEM24 have been

identified in PM PPIn re-synthesis after activation of phospholipase C (Lees et al., 2017b;

Dornan et al., 2018). Intriguingly, several of these studies found that simple over-expression of

these transfer proteins can accelerate synthesis or elevate steady-state levels of PM PPIn

(Chang et al., 2013; Kim et al., 2015; Lees et al., 2017a). Such observations are easily

explained when viewed through the prism of our findings, which demonstrate a limited supply of

PI at the PM; expanding the supply process is thus expected to increase synthesis or steady-

state levels. However, they do not explain how cells control steady-state PI4P and $PI(4,5)P_2$

accumulation. Recently, a regulatory mechanism that puts a break on PI4P catabolism at the

PM when levels of $PI(4,5)P_2$ drop has been demonstrated (Sohn et al., 2018). However, what

homeostatic mechanism(s) maintain steady state levels of $PI(4,5)P_2$, and how this mechanism

couples to the transport of PI to the PM, is a significant question for the future.

Acknowledgments

We thank colleagues cited in the Materials and methods for generously sharing plasmids. This work was supported by National Institutes of Health grant 1R35GM119412-01 (to G.R.V.H.).

Author Contributions

J. P. Zewe, R. C. Wills, B.D. Goulden, G.R.V. Hammond conceived of the experiments and developed methods. J.P. Zewe, A. Miller, S. Sangappa, R. C. Wills and G.R.V. Hammond performed experiments. J.P. Zewe, A. Miller, S. Sangappa, R. C. Wills and G.R.V. Hammond analyzed data. G.R.V. Hammond acquired grant funding for this study. G.R.V. Hammond wrote the original draft of the manuscript; All authors reviewed and edited the manuscript.

Conflict of Interest

The authors declare no competing financial interests.

Materials and Methods

Plasmids and Cloning

Production of new plasmids for this study was accomplished by standard restriction-ligation or NEBuilder HiFi DNA Assembly (New England Biolabs E5520S), typically using Clontech pEGFP-C1 and -N1 backbones or their derivatives. Our standard fluorophores were a human codon optimized EGFP derived from *Aequorea victoria* GFP containing F64L and S65T mutations (Cormack et al., 1996), a *Discoma* DsRed monomeric variant known as mCherry (Shaner et al., 2004), the iRFP variant derived from *Rhodopseudomonas palustris* bacteriophytochrome BphP2 (Filonov et al., 2011), and mTagBFP2 derived from *Entacmaea quadricolor* protein eqFP578 (Subach et al., 2011). Mutated constructs were generated by site-directed mutagenesis using targeted pairs of DNA oligos. All custom oligos were supplied by ThermoFisher. After cloning, all constructs were sequence verified by Sanger DNA sequencing. Plasmids constructed for this study are available through Addgene (www.addgene.org). Table 2 lists all plasmids used in this study and their respective sources.

Chemicals and Reagents

For chemical dimerization experiments, Rapamycin (Fisher Scientific BP2963-1) was dissolved

to 1 mM in DMSO as a stock and used at a final concentration of 1 μM in cells. Carbachol

(Fisher Scientific AC10824-0050) was prepared by dissolving in water to 50 mM and stored at -

20°C. Atropine (Fisher Scientific AC226680100) was dissolved to 25 mM in 100% ethanol and

stored at -20°C. 30% H_2O_2 (EMD Millipore HX0635-3) was stored at 4°C and prepared fresh in

complete imaging media when used as an additive. A1 PI4KA inhibitor (Bojjireddy et al., 2014),

a kind gift from Tamas Balla, was dissolved in DMSO to a 100 μM stock and stored at -20°C.

Cell Culture and Lipofection

COS-7 (ATCC CRL-1651) cells were cultured at 37°C with a humidified 5% CO_2 atmosphere in

low glucose DMEM (ThermoFisher 10567022) supplemented with 10% heat-inactivated fetal

bovine serum (ThermoFisher 10438-034), 100 units/mL Penicillin-Streptomycin (ThermoFisher

15140122) and 0.1% chemically defined lipid supplement (ThermoFisher 11905031). Cells

were passaged two times a week 1:5 in culture-treated flasks using TrypLE dissociation media

(ThermoFisher 12604039).

In preparation for imaging, cells were seeded onto 35 mm #1.5 cover glass bottom dishes

(CellVis D35-20-1.5-N) pre-coated with 5 μg of human fibronectin (ThermoFisher 33016-015)

dissolved in water. Once adherent and between 50% - 80% confluent, cells were transfected

according to manufacturer's instructions using 1 μg of total DNA complexed with 3 μg

Lipofectamine2000 (ThermoFisher 11668019) in 200 μL Opti-MEM (ThermoFisher 51985091).

Imaging of transfected samples occurred after an incubation time of ~18-24 hr.

Fluorescent Lipids

TopFluor® conjugated PI, PS, and PI(4,5)P$_2$ were obtained from Avanti Polar Lipids Inc.

(810187P, 810283P, 810184P). Lipid-BSA complexing was accomplished using 5 μM (0.34

mg/ml) fatty acid-free BSA (Sigma 126575) dissolved in PBS with 3 mM EGTA. Fluorescent

lipids were sonicated in methanol at a concentration of 1 mM before injecting 5 μl into 1 ml

BSA/PBS mixture and vortexed at medium to high speed and incubated at 37°C for 20-30 min.

Back-extraction media was made using 17 mg/mL fatty acid-free BSA (i.e. 250 μM, 5 x the final

concentration applied to cells) in serum-free imaging media and filtered.

Thin-layer Chromatography

LK6D 60 Å silica gel 20 x 20 cm glass-backed TLC plates (Whatman 4865-821) were prepared

by dipping into 74 mM sodium oxalate in 0.5% boric acid and dried overnight. Before loading,

plates were pre-equilibrated in a 70:70:4:16 chloroform, methanol, ammonium hydroxide and

water mixture. After loading, the plates were run in the same solvent mixture, then removed and

allowed to dry for 15 min at room temperature in a fume hood. Fluorescent lipids were imaged

using a ChemiDoc MP imaging system (BioRad) using 460-490 nm LED epi-illumination and a

518-546 nm emission filter.

Cells were extracted using a modified protocol (Lees et al., 1959). Briefly, cells in 35 mm glass

bottom dishes were lysed in 250 μl 1 M HCl, scraped and collected in polypropylene tubes. The

dishes were rinsed with 333 μl methanol, which was then pooled with the HCl extract. 667 μl

chloroform was then added to the extracts before samples were vortexed vigorously and

centrifuged to resolve two phases. The lower phase was removed and washed with 3:48:47

chloroform:methanol:1M HCl, and the upper phase re-extracted with 86:14:1

chloroform:methanol:1M HCl. After re-centrifuging to resolve phases, the washed lower phase

was transferred to a fresh polypropylene tube, and the re-extracted upper phase was washed.

This washed re-extract was pooled with the original extract and dried under nitrogen. Samples

were re-dissolved in 30 μL of a 86:14:1 mixture of chloroform, methanol and 1M HCl and

streaked into the concentration zone of the TLC plate to run.

Microscopy

For all live-cell imaging, standard growth medium was replaced with Fluorobrite DMEM

(ThermoFisher A1896702) supplemented with 10% heat-inactivated fetal bovine serum, 25mM

HEPES (pH 7.4), 0.1% chemically defined lipid supplement and 2 mM Glutamax (ThermoFisher

35050061). Initial volume of imaging media was adjusted so that 2 mL total volume was

achieved after all chemical additions for a given experiment.

Confocal imaging was accomplished on a Nikon TiE A1R platform acquiring images in resonant

mode with a 100X 1.45 NA plan-apochromatic objective. Signal to noise ratio was improved by

taking 8 frame averages. Excitation of fluorophores was accomplished via a dual fiber-coupled

LUN-V laser launch with 405 nm (BFP), 488 nm (GFP), 561 nm (mCherry) and 640nm (iRFP)

lines. Emission was collected through dual pass filters from Chroma: blue/yellow-orange (420-

480 nm / 570-620 nm) and green/far-red (505-550 nm / 650-850 nm). Confocal pinhole size was

defined as 1.2X the Airy disc size of the longest wavelength channel used in the experiment.

Nikon Elements software was used to acquire images for all experiments. All data were saved

with the file extension .nd2.

An independent Nikon TiE platform coupled with a TIRF illuminator arm (Nikon) and 100X 1.45

NA plan-apochromatic objective was used to acquire TIRFM imaging data. Excitation of

fluorophores was accomplished via an Oxxius L4C laser launch with 405nm (BFP), 488 nm

(EGFP), 561nm (mCherry) and 638nm (iRFP) lines. Emission was collected through dual pass

filters from Chroma: blue/yellow-orange (420-480 nm / 570-620 nm) and green/far-red (505-550

nm / 650-850 nm). A Zyla 5.5 sCMOS camera (Andor) was used to capture images, binning

2X2. Nikon Elements software was used to acquire images for all experiments. All data were

saved with the file extension .nd2.

Image Analysis

Analysis of images was accomplished in Fiji software (Schindelin et al., 2012). A custom macro

was written to generate channel-specific montages and display all xy positions captured in a

given experiment in concatenated series. Individual regions of interest (ROI) were then

generated around cells displayed in these montages.

The ratio of fluorescence intensity between specific compartments in confocal images were

analyzed as described previously (Zewe et al., 2018). A custom macro was used to generate a

binary mask through à trous wavelet decomposition (Olivo-Marin, 2002). The mask was applied

to measure fluorescence intensity within a given compartment, while normalizing to the ROI's

mean pixel intensity to account for variance in expression level present in transient

transfections.

To analyze TIRFM images, a minimum intensity projection was used as the basis to generate

ROIs within the footprint of individual cells. Background fluorescence values were measured

and subtracted from images at all time-points. Fluorescence values were then normalized to

the ROI's mean pixel intensity of time-points preceding treatment or stimulation.

For statistical analysis and generation of graphs and plots, quantitative data was imported into

Prism 8 (GraphPad). For area under the curve (AUC) analysis, baseline-corrected data were

first sorted into groups of individual curves. The net area under the curve for each ROI was

then pooled and compared among conditions. D'Agostino and Pearson normality tests returned

values that significantly varied from a normal distribution, so data were subjected to a non-

parametric Kruskal-Wallis test and if significant variance between medians was found, Dunn's

multiple comparisons test was run post-hoc.

All representative images were selected based on a robust signal to noise ratio, typical

morphology and fluorescence measurements near the median of its cohort. Any adjustments

made to brightness or contrast to ease visibility were made in a linear fashion across the entire

image.

Supplementary material

Figure S1 shows controls for cross-talk for the data presented in figure 1C-E. Figure S2 shows

the kinetics of recruitment of split-PI-PLC to organelle-specific compartments. Figures S3 and

S4 show kinetics of recruitment of FKBP-PI4KA and -PI4KB, respectively.

References

Alwarawrah M, Hussain F, Huang J. 2016. Alteration of lipid membrane structure and dynamics by diacylglycerols with unsaturated chains. *Biochimica Biophys Acta* **1858**:253–263. doi:10.1016/j.bbamem.2015.11.014

Anderson KE, Kielkowska A, Durrant TN, Juvin V, Clark J, Stephens L, Hawkins PT. 2013. Lysophosphatidylinositol-Acyltransferase-1 (LPIAT1) Is Required to Maintain Physiological Levels of PtdIns and PtdInsP2 in the Mouse. *PLoS ONE* **8**:e58425. doi:10.1371/journal.pone.0058425

Bai J, Pagano RE. 1997. Measurement of Spontaneous Transfer and Transbilayer Movement of BODIPY-Labeled Lipids in Lipid Vesicles†. *Biochemistry* **36**:8840–8848. doi:10.1021/bi970145r

Balla A, Balla T. 2006. Phosphatidylinositol 4-kinases: old enzymes with emerging functions. *Trends Cell Biology* **16**:351–361. doi:10.1016/j.tcb.2006.05.003

Balla T. 2013. Phosphoinositides: Tiny Lipids With Giant Impact on Cell Regulation. *Physiol Rev* **93**:1019–1137. doi:10.1152/physrev.00028.2012

Balla T, Bondeva T, Várnai P. 2000. How accurately can we image inositol lipids in living cells? *Trends Pharmacol Sci* **21**:238–241. doi:10.1016/s0165-6147(00)01500-5

Bochud A, Conzelmann A. 2015. The active site of yeast phosphatidylinositol synthase Pis1 is facing the cytosol. *Biochim Biophys Acta* **1851**. doi:10.1016/j.bbalip.2015.02.006

Bojjireddy N, Botyanszki J, Hammond G, Creech D, Peterson R, Kemp DC, Snead M, Brown R, Morrison A, Wilson S, Harrison S, Moore C, Balla T. 2014. Pharmacological and Genetic Targeting of the PI4KA Enzyme Reveals Its Important Role in Maintaining Plasma Membrane Phosphatidylinositol 4-Phosphate and Phosphatidylinositol 4,5-Bisphosphate Levels. *J Biol Chem* **289**:6120–6132. doi:10.1074/jbc.m113.531426

Bütikofer P, Lin Z, Chiu D, Lubin B, Kuypers F. 1990. Transbilayer distribution and mobility of phosphatidylinositol in human red blood cells. *J Biol Chem* **265**:16035–8.

Chang C-L, Hsieh T-S, Yang TT, Rothberg KG, Azizoglu BD, Volk E, Liao J-C, Liou J. 2013. Feedback Regulation of Receptor-Induced Ca2+ Signaling Mediated by E-Syt1 and Nir2 at Endoplasmic Reticulum-Plasma Membrane Junctions. *Cell Rep* **5**:813–825. doi:10.1016/j.celrep.2013.09.038

Cormack BP, Valdivia RH, Falkow S. 1996. FACS-optimized mutants of the green fluorescent protein (GFP). *Gene* **173**:33–38. doi:10.1016/0378-1119(95)00685-0

Courtney T, Deiters A. 2018. Recent advances in the optical control of protein function through genetic code expansion. *Curr Opin Chem Biol* **46**:99–107. doi:10.1016/j.cbpa.2018.07.011

DeRose R, Miyamoto T, Inoue T. 2013. Manipulating signaling at will: chemically-inducible dimerization (CID) techniques resolve problems in cell biology. *Pflügers Arch* **465**:409–417. doi:10.1007/s00424-012-1208-6

1 Dickson EJ, Hille B. 2019. Understanding phosphoinositides: rare, dynamic, and essential
2 membrane phospholipids. *Biochem J* **476**:1–23. doi:10.1042/BCJ20180022
3
4 Dickson EJ, Jensen JB, Hille B. 2014. Golgi and plasma membrane pools of PI(4)P contribute to
5 plasma membrane PI(4,5)P2 and maintenance of KCNQ2/3 ion channel current. *Proc Natl Acad*
6 *Sci* **111**:E2281–E2290. doi:10.1073/pnas.1407133111
7
8 Dong R, Saheki Y, Swarup S, Lucast L, Harper WJ, De Camilli P. 2016. Endosome-ER
9 Contacts Control Actin Nucleation and Retromer Function through VAP-Dependent Regulation
10 of PI4P. *Cell* **166**:408–423. doi:10.1016/j.cell.2016.06.037
11
12 Dornan GL, Dalwadi U, Hamelin DJ, Hoffmann RM, Yip CK, Burke JE. 2018. Probing the
13 Architecture, Dynamics, and Inhibition of the PI4KIIIα/TTC7/FAM126 Complex. *J Mol Biol*
14 **430**:3129–3142. doi:10.1016/j.jmb.2018.07.020
15
16 Ferrell J, Huestis W. 1984. Phosphoinositide metabolism and the morphology of human
17 erythrocytes. *J Cell Biol* **98**:1992–1998. doi:10.1083/jcb.98.6.1992
18
19 Filonov GS, Piatkevich KD, Ting L-M, Zhang J, Kim K, Verkhusha VV. 2011. Bright and stable
20 near-infrared fluorescent protein for in vivo imaging. *Nat Biotechnol* **29**:757–761.
21 doi:10.1038/nbt.1918
22
23 Gässler CS, Ryan M, Liu T, Griffith HO, Heinz DW. 1997. Probing the Roles of Active Site
24 Residues in Phosphatidylinositol-Specific Phospholipase C fromBacillus cereusby Site-Directed
25 Mutagenesis†. *Biochemistry* **36**:12802–12813. doi:10.1021/bi971102d
26
27 Goulden BD, Pacheco J, Dull A, Zewe JP, Deiters A, Hammond G. 2018. A high-avidity
28 biosensor reveals plasma membrane PI(3,4)P2 is predominantly a class I PI3K signaling
29 product. *J Cell Biol*. doi:10.1083/jcb.201809026
30
31 Grabon A, Khan D, Bankaitis VA. 2015. Phosphatidylinositol transfer proteins and instructive
32 regulation of lipid kinase biology. *Biochim Biophys Acta* **1851**:724–735.
33 doi:10.1016/j.bbalip.2014.12.011
34
35 Griffiths G, Back R, Marsh M. 1989. A quantitative analysis of the endocytic pathway in baby
36 hamster kidney cells. *J Cell Biol* **109**:2703–2720. doi:10.1083/jcb.109.6.2703
37
38 Hammond G, Balla T. 2015. Polyphosphoinositide binding domains: Key to inositol lipid biology.
39 *Biochim Biophys Acta* **1851**:746–758. doi:10.1016/j.bbalip.2015.02.013
40
41 Hammond G, Machner MP, Balla T. 2014. A novel probe for phosphatidylinositol 4-phosphate
42 reveals multiple pools beyond the Golgi. *J Cell Biol* **205**:113–126. doi:10.1083/jcb.201312072
43
44 Harak C, Radujkovic D, Taveneau C, Reiss S, Klein R, Bressanelli S, Lohmann V. 2014.
45 Mapping of Functional Domains of the Lipid Kinase Phosphatidylinositol 4-Kinase Type III Alpha
46 Involved in Enzymatic Activity and Hepatitis C Virus Replication. *J Virol* **88**:9909–9926.
47 doi:10.1128/jvi.01063-14
48
49 Hsu F, Hu F, Mao Y. 2015. Spatiotemporal control of phosphatidylinositol 4-phosphate by Sac2
50 regulates endocytic recycling. *J Cell Biol* **209**:97–110. doi:10.1083/jcb.201408027
51

1   Jović M, Kean MJ, Szentpetery Z, Polevoy G, Gingras A-C, Brill JA, Balla T. 2012. Two
2   phosphatidylinositol 4-kinases control lysosomal delivery of the Gaucher disease enzyme, β-
3   glucocerebrosidase. *Mol Biol Cell* **23**:1533–1545. doi:10.1091/mbc.e11-06-0553
4
5   Kay JG, Koivusalo M, Ma X, Wohland T, Grinstein S. 2012. Phosphatidylserine dynamics in
6   cellular membranes. *Mol Biol Cell* **23**:2198–2212. doi:10.1091/mbc.E11-11-0936
7
8   Kim Y, Guzman-Hernandez M, Balla T. 2011. A Highly Dynamic ER-Derived
9   Phosphatidylinositol-Synthesizing Organelle Supplies Phosphoinositides to Cellular
10 Membranes. *Dev Cell* **21**:813–824. doi:10.1016/j.devcel.2011.09.005
11
12 Kim Y, Guzman-Hernandez M-L, Wisniewski E, Balla T. 2015. Phosphatidylinositol-
13 Phosphatidic Acid Exchange by Nir2 at ER-PM Contact Sites Maintains Phosphoinositide
14 Signaling Competence. *Dev Cell* **33**:549–561. doi:10.1016/j.devcel.2015.04.028
15
16 Lange Y, aisgood, Ramos B, Steck T. 1989. Plasma membranes contain half the phospholipid
17 and 90% of the cholesterol and sphingomyelin in cultured human fibroblasts. *J Biol Chem*
18 **264**:3786–93.
19
20 Lapetina EG, Michell RH. 1973. Phosphatidylinositol metabolism in cells receiving extracellular
21 stimulation. *FEBS Lett* **31**:1–10. doi:10.1016/0014-5793(73)80061-4
22
23 Lees JA, Messa M, Sun E, Wheeler H, Torta F, Wenk MR, Camilli P, Reinisch KM. 2017a. Lipid
24 transport by TMEM24 at ER–plasma membrane contacts regulates pulsatile insulin secretion.
25 *Science* **355**:eaah6171. doi:10.1126/science.aah6171
26
27 Lees JA, Zhang Y, Oh MS, Schauder CM, Yu X, Baskin JM, Dobbs K, Notarangelo LD, Camilli
28 P, Walz T, Reinisch KM. 2017b. Architecture of the human PI4KIIIα lipid kinase complex. *Proc*
29 *Natl Acad Sci* **114**:13720–13725. doi:10.1073/pnas.1718471115
30
31 LEES M, FOLCH J, STANLEY SG, CARR S. 1959. A SIMPLE PROCEDURE FOR THE
32 PREPARATION OF BRAIN SULPHATIDES*. *J Neurochem* **4**:9–18. doi:10.1111/j.1471-
33 4159.1959.tb13169.x
34
35 Lipsky N, Pagano R. 1985. A vital stain for the Golgi apparatus. *Science* **228**:745–747.
36 doi:10.1126/science.2581316
37
38 Luo X, Wasilko DJ, Liu Y, Sun J, Wu X, Luo Z-Q, Mao Y. 2015. Structure of the Legionella
39 Virulence Factor, SidC Reveals a Unique PI(4)P-Specific Binding Domain Essential for Its
40 Targeting to the Bacterial Phagosome. *PLOS Pathog* **11**:e1004965.
41 doi:10.1371/journal.ppat.1004965
42
43 Ma Y, Taylor S. 2002. A 15-Residue Bifunctional Element in d-AKAP1 Is Required for Both
44 Endoplasmic Reticulum and Mitochondrial Targeting. *J Biol Chem* **277**:27328–27336.
45 doi:10.1074/jbc.m201421200
46
47 Martin O, Pagano R. 1987. Transbilayer movement of fluorescent analogs of phosphatidylserine
48 and phosphatidylethanolamine at the plasma membrane of cultured cells. Evidence for a
49 protein-mediated and ATP-dependent process(es). *J Biol Chem* **262**:5890–8.
50
51 Michell RH. 2018. Do inositol supplements enhance phosphatidylinositol supply and thus

support endoplasmic reticulum function? *Br J Nutr* **120**. doi:10.1017/S0007114518000946

Moser J, Gerstel B, Meyer J, Chakraborty T, Wehland J, Heinz DW. 1997. Crystal structure of the phosphatidylinositol-specific phospholipase C from the human pathogen Listeria monocytogenes11Edited by R. Huber. *J Mol Biol* **273**:269–282. doi:10.1006/jmbi.1997.1290

Nakanishi S, Catt K, Balla T. 1995. A wortmannin-sensitive phosphatidylinositol 4-kinase that regulates hormone-sensitive pools of inositolphospholipids. *Proc Natl Acad Sci* **92**:5317–5321. doi:10.1073/pnas.92.12.5317

Nakatsu F, Messa M, Nández R, Czapla H, Zou Y, rittmatter S, Camilli P. 2015. Sac2/INPP5F is an inositol 4-phosphatase that functions in the endocytic pathway. *J Cell Biol* **209**:85–95. doi:10.1083/jcb.201409064

Nasuhoglu C, Feng S, Mao Y, Shammat I, Yamamato M, Earnest S, Lemmon M, Hilgemann DW. 2002. Modulation of cardiac PIP2 by cardioactive hormones and other physiologically relevant interventions. *American J Physiol Cell Physiol* **283**:C223–C234. doi:10.1152/ajpcell.00486.2001

Olivo-Marin J-C. 2002. Extraction of spots in biological images using multiscale products. *Pattern Recogn* **35**:1989–1996. doi:10.1016/s0031-3203(01)00127-3

Olkkonen VM. 2015. OSBP-Related Protein Family in Lipid Transport over Membrane Contact Sites. *Lipid insights* **8**:1–9. doi:10.4137/LPI.S31726

Pagano R, Longmuir K, Martin O. 1983. Intracellular translocation and metabolism of a fluorescent phosphatidic acid analogue in cultured fibroblasts. *J Biol Chem* **258**:2034–40.

Quinn KV, Behe P, Tinker A. 2008. Monitoring changes in membrane phosphatidylinositol 4,5-bisphosphate in living cells using a domain from the transcription factor tubby. *J Physiol* **586**:2855–2871. doi:10.1113/jphysiol.2008.153791

Saheki Y, Bian X, Schauder CM, Sawaki Y, Surma MA, Klose C, Pincet F, Reinisch KM, DeCamilli P. 2016. Control of plasma membrane lipid homeostasis by the extended synaptotagmins. *Nat Cell Biol* **18**:504–515. doi:10.1038/ncb3339

Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez J-Y, White D, Hartenstein V, Eliceiri K, Tomancak P, Cardona A. 2012. Fiji: an open-source platform for biological-image analysis. *Nat Methods* **9**:676. doi:10.1038/nmeth.2019

Schmick M, Vartak N, Papke B, Kovacevic M, Truxius DC, Rossmannek L, Bastiaens PI. 2014. KRas Localizes to the Plasma Membrane by Spatial Cycles of Solubilization, Trapping and Vesicular Transport. *Cell* **157**:459–471. doi:10.1016/j.cell.2014.02.051

Shaner NC, Campbell RE, Steinbach PA, Giepmans BN, Palmer AE, Tsien RY. 2004. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. *Nat Biotechnol* **22**:1567–1572. doi:10.1038/nbt1037

Sohn M, Korzeniowski M, Zewe JP, Wills RC, Hammond G, Humpolickova J, Vrzal L, Chalupska D, Veverka V, Fairn GD, Boura E, Balla T. 2018. PI(4,5)P2 controls plasma

membrane PI4P and PS levels via ORP5/8 recruitment to ER–PM contact sites. *J Cell Biol* jcb.201710095. doi:10.1083/jcb.201710095

Struck D, Pagano R. 1980. Insertion of fluorescent phospholipids into the plasma membrane of a mammalian cell. *J Biol Chem* **255**:5404–10.

Subach OM, Cranfill PJ, Davidson MW, Verkhusha VV. 2011. An Enhanced Monomeric Blue Fluorescent Protein with the High Chemical Stability of the Chromophore. *Plos One* **6**:e28674. doi:10.1371/journal.pone.0028674

Szentpetery Z, Várnai P, Balla T. 2010. Acute manipulation of Golgi phosphoinositides to assess their importance in cellular trafficking and signaling. *Proc Natl Acad Sci* **107**:8225–8230. doi:10.1073/pnas.1000157107

Ting A, Pagano R. 1990. Detection of a phosphatidylinositol-specific phospholipase C at the surface of Swiss 3T3 cells and its potential role in the regulation of cell growth. *J Biol Chem* **265**:5337–40.

Traynor-Kaplan A, Kruse M, Dickson EJ, Dai G, Vivas O, Yu H, Whittington D, Hille B. 2017. Fatty-acyl chain profiles of cellular phosphoinositides. *Biochim biophys acta* **1862**:513–522. doi:10.1016/j.bbalip.2017.02.002

Valm AM, Cohen S, Legant WR, Melunis J, Hershberg U, Wait E, Cohen AR, Davidson MW, Betzig E, Lippincottschwartz J. 2017. Applying systems-level spectral imaging and analysis to reveal the organelle interactome. *Nature* **546**:162–167. doi:10.1038/nature22369

Vance JE. 2015. Phospholipid Synthesis and Transport in Mammalian Cells. *Traffic* **16**. doi:10.1111/tra.12230

Vishwakarma RA, Vehring S, Mehta A, Sinha A, Pomorski T, Herrmann A, Menon AK. 2005. New fluorescent probes reveal that flippase-mediated flip-flop of phosphatidylinositol across the endoplasmic reticulum membrane does not depend on the stereochemistry of the lipid. *Org Biomol Chem* **3**:1275–1283. doi:10.1039/B500300H

Wang L, Iwasaki Y, Andra KK, Pandey K, Menon AK, Bütikofer P. 2018. Scrambling of natural and fluorescently tagged phosphatidylinositol by reconstituted G protein–coupled receptor and TMEM16 scramblases. *J Biol Chem* **293**:18318–18327. doi:10.1074/jbc.RA118.004213

Weber S, Wagner M, Hilbi H. 2014. Live-Cell Imaging of Phosphoinositide Dynamics and Membrane Architecture during Legionella Infection. *Mbio* **5**:e00839-13. doi:10.1128/mbio.00839-13

Willars G, Nahorski S, Challiss R. 1998. Differential regulation of muscarinic acetylcholine receptor-sensitive polyphosphoinositide pools and consequences for signaling in human neuroblastoma cells. *J Biol Chem* **273**:5037–46.

Yadav S, Garner K, Georgiev P, Li M, Gomez-Espinosa E, Panda A, Mathre S, Okkenhaug H, Cockcroft S, Raghu P. 2015. RDGBα, a PtdIns-PtdOH transfer protein, regulates G-protein-coupled PtdIns(4,5)P2 signalling during Drosophila phototransduction. *J Cell Sci* **128**:3330–3344. doi:10.1242/jcs.173476

1 Zewe JP, Wills RC, Sangappa S, Goulden BD, Hammond GR. 2018. SAC1 degrades its lipid
2 substrate PtdIns4P in the endoplasmic reticulum to maintain a steep chemical gradient with
3 donor membranes. *eLife* **7**. doi:10.7554/eLife.35588

Organelle	Is **PI detected** with the indicated method?			Possible reasons for discrepancy
	TopFluor-PI	**PI-PLC:** PI→DAG	**PI4K:** PI→PI4P	
Golgi	**Yes**	**Yes**	**Yes**	No discrepancy
Lysosomes	*Not tested*	**Yes**	***Trace***	PI4P phosphatase e.g. SAC2?
Endosomes	*Not tested*	**Yes**	***Trace***	PI4P phosphatase e.g. SAC2?
Mitochondria	**Yes**	**Yes***	**Yes**	No discrepancy
Peroxisomes	*Not tested*	***Trace***	**Yes**	Failure to target PI-PLC to peroxisomes?
ER	**Yes**	***Trace***	**Yes#**	Failure to target PI-PLC to ER?
PM	Not detected	***Trace‡***	Not detected	PI level beneath threshold of detection?

Table 1: summary of results. Results were characterized as "yes" when substantial and statistically significant
signal was observed and "not detected" when signal was neither significant nor substantial. We use "trace" to denote
situations where statistically significant but small signals ($\Delta F/F_{pre}$ < 10%) were observed. "Not detected" refers to
situations where no accumulation of signal was observed. Note that for TopFluor-PI, not all organelles were
interrogated. *only detected after forced targeting of PI-PLC to the mitochondrial surface. #only detected after
treatment of cells with 500 μM peroxide to inhibit endogenous PI4P phosphatase SAC1. ‡Only detected transiently
after forced targeting of PI-PLC to the PM with a DAG sensor, and inferred by accumulation of DAG-regulated PI/PA
transfer protein Nir2.

Plasmid	Vector	Insert	Reference
NES-EGFP-P4Mx1	pEGFP-C1	*X.leavis map2k1.L(32-44):EGFP:L. pneumophila SidM(546-647)*	(Sohn et al., 2018)
Lyn^{N11}-FRB-iRFP	piRFP-N1	*LYN(1-11):MTOR(2021-2113):iRFP*	(Hammond et al., 2014)
LAMP1-FRB-iRFP	piRFP-N1	*LAMP1:MTOR(2021-2113):iRFP*	(Goulden et al., 2018)
EGFP-FYVE-EEA1	pEGFP-C1	*EGFP:EEA1(1253-1411)*	(Balla et al., 2000)
NES-EGFP-P4Mx1	pEGFP-C1	*X.leavis map2k1.L*(32-44):EGFP:*L. pneumophila SidM*(546-647)	(Zewe et al., 2018)
mCherry-Rab5	pmCherry-C1	*mCherry:Canis lupus RAB5A*	(Hammond et al., 2014)
iRFP-N1-PI-PLC^{C100}-FRB	piRFP-N1	*L. monocytogenes PI-PLC(188-287)*:IGTAGPRSANS[GA]$_4$*: MTOR(2021-2113):iRFP*	(This study)
TagBFP2-C1-FKB-PI-PLC^{N187}	pTagBFP-C1	*TagBFP2:FKBP1A(3-108):*[GGSA]$_4$GG*:L. monocytogenes PI-PLC(1-187)*	(This study)
pTagBFP2-C1-lynN^{11}-FKBP-PI-PLC^{N187}	pTagBFP-C1	*LYN(1-11)*:RSANS[GA]$_4$:*TagBFP2: FKBP1A(3-108):* [GGSA]$_4$GG*:L. monocytogenes PI-PLC(1-187)*	(This study)
pTagBFP2-C1-AKAP1^{N31}-FKBP-PI-PLC^{N187}	pTagBFP-C1	*Mus musculus Akap1*(1-31) M16L: PTRSANS[GA]$_4$ILSRM*:TagBFP2: FKBP1A(3-108):* [GGSA]$_4$GG*:L. monocytogenes PI-PLC(1-187)*	(This study)
mCherry-Rab7	pmCherry-C1	*mCherry:Canis lupus RAB7A*	(Hammond et al., 2014)
mCherry-FKBP-PI4KB	pmCherry-C1	mCherry: *TagBFP2: FKBP1A(3-108):* GGSA]$_4$GG*:PI4KB*	(This Study)
mCherry-FKBP-PI4KA^{C1001}	pmCherry-C1	mCherry: *TagBFP2: FKBP1A(3-108):* GGSA]$_4$GG*:PI4KA(1102-2103)*	(This Study)
mCherry-FKBP-PI4KA$^{C1001-D1957A}$	pmCherry-C1	mCherry: *TagBFP2: FKBP1A(3-108):* GGSA]$_4$GG*:PI4KA(1102-2103)-Asp1957Ala*	(This Study)
piRFP-FRB-Giantin	piRFP-C1	iRFP*:MTOR*(2021-2113):[GGSA]$_2$:*GOLGB1*(3097-3226)	(This study)
pmCherry-C1ab-Prkd1	pmCherry-C1	mCherry:*Mus musculus Prkd1*(138-343)	(This study)
NES-GFP-C1ab-Prkd1	pEGFP-C1	EGFP:*Mus musculus Prkd1*(138-343)	(Kim et al., 2011)
Tubby$_c$-mCherry	pEGFP-N1	*Mus musculus Tub(243-505):mCherry*	(Quinn et al., 2008)
Tubby$_c^{R332H}$-mCherry	pEGFP-N1	*Mus musculus Tub*(243-505) R332H:mCherry	(Quinn et al., 2008)
Akap1(31)-FRB-iRFP	piRFP-N1	*Mus musculus Akap1*(1-31) M16L:*MTOR(2021-2113):iRFP*	(This study)
piRFP-FRB-PMP-C-10	piRFP-C1	iRFP: *MTOR*(2021-2113):[GGSA]$_2$QASNSAVSGLRSGSSGG:*PXMP*(2-195)	(This study)
iRFP-FRB-ER	piRFP-C1	iRFP:*MTOR*(2021-2113):[GGSA]$_2$ILNSRV:*SACM1L*(521-587)	(This study)
β4-GalT^{N82}-mCherry	pmCherry-N1	*B4GALT(1-82):mCherry*	Addgene #55052*
iRFP-Sec61β	piRFP-C1	iRFP:*SEC61B*	(Zewe et al., 2018)
COX8A^{N29}x2-mCherry	pmCherry-N1	*COX8A(1-29):mCherry*	This study

MannII[N21]-mKO2	pmKO2-N1	*Mus musculus Man2a*(1-102):*Kusabira Orange2:*	Addgene #57881*
LAMP1-mRFP	pmRFP-N1	*LAMP1:mRFP*	(Jović et al., 2012)
mCherry-PMP	pmCherry-C1	mCherry:SGLRSRAQASNSAV:*PXMP*(2-195)	
mCherry-VAPB	pmCherry-C1	mCherry:*VAPB*	(Zewe et al., 2018)
HAx3-AChR-M3	pcDNA3.1	HAx3:CHRM3(2-590)	J.Wes
EGFP-Nir2	EGFP	*EGFP:PITPNM1*	(Kim et al., 2015)

1   **Table 2. Plasmids used in this study**. *B4-GalT[N82]-mCherry (Addgene plasmid #55052; RRID:Addgene_55052)

2   and MannII[N21]-KO2 (Addgene plasmid #57881; RRID:Addgene_57881) were gifts from Michael Davidson.

Supplementary Material

Figure S1: TopFluor-PI fluorescence distribution is not contaminated by bleed-through from transfected organelle markers. Images show a non-transfected cell imaged under identical conditions to those presented in figure 1. Clear mitochondrial (i), Golgi (ii) and ER (III) morphology of the green fluorescence is seen even with no expression of markers for these compartments, demonstrating that they are not due to fluorescence bleed-through. N.B. mitochondrial morphology is evident from the differential interference contrast image (gray). Insets are 7.3 μm and serve as scale bar.

Figure S2: Kinetics of PI-PLC^{C100}-FRB-iRFP recruitment to organelle-targeted BFP-FKBP-PI-PLC^{N187} (**A**) **schematic**. (**B**) **Summary data**. Mean time constant ± 95% confidence interval (CI) is shown for each organelle-targeted construct. (**C and D**) Data for C1ab recruitment as shown in (C) figures 3A and (D) figure 2C is shown alongside that for PI-PLC^{C100}-FRB-iRFP from the same cells. Data are means with s.e.m. shaded; black fits represent the mean fit for all cells to the single-phase exponential ΔIntensity = Plateau x $e^{-(time/\tau)}$.

Figure S3: Kinetics of mCherry-FKBP-PI4KA[C1001] recruitment to organelle-targeted FRB (**A**) **schematic**. (**B**)
Summary data. Mean time constant ± 95% confidence interval (CI) is shown for each organelle-targeted construct.
(**C-I**) Data for PI4P biosensor (green) recruitment as shown in (C) figure 6A and (D-I) figure 5B is shown alongside
that for mCherry-FKBP-PI4KA[C1001] (orange) from the same cells. Data are means with s.e.m. shaded; black fits
represent the mean fit for all cells to the single-phase exponential ΔIntensity = Plateau x $e^{-(time/\tau)}$.

Figure S4: Kinetics of mCherry-FKBP-PI4KB recruitment to organelle-targeted FRB (**A**) **schematic**. (**B**)
Summary data. Mean time constant ± 95% confidence interval (CI) is shown for PM (**C**) and mitochondria (**D**). Data
for GFP-P4Mx1 PI4P biosensor (green) recruitment as shown figure 6B is shown alongside that for mCherry-FKBP-
PI4KB (maroon) from the same cells. Data are means with s.e.m. shaded; black fits represent the mean fit for all cells
to the single-phase exponential ΔIntensity = Plateau x $e^{-(time/\tau)}$.